Novo Nordisk A/S (NYSE:NVO) Given Overweight Rating at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Novo Nordisk A/S (NYSE:NVO – Free Report) in a report released on Monday, Benzinga reports. Cantor Fitzgerald currently has a $160.00 price target on the stock. Several other brokerages have also commented on NVO. StockNews.com lowered Novo Nordisk A/S from a strong-buy rating to a buy […]

Leave a Reply

Your email address will not be published.

Previous post Victory Capital Holdings, Inc. (NASDAQ:VCTR) Given Consensus Rating of “Hold” by Brokerages
Next post Energy Transfer LP (NYSE:ET) Given Average Recommendation of “Moderate Buy” by Analysts